From Robust Clone Outgrowth to GMP-Ready Cell Banks
Ensuring the clinical reliability of iPSC-derived products begins with genetically stable and well-characterized starting materials.
This webinar presents a multilayer strategy designed to safeguard the genomic integrity of iPSCs and examines a Master Cell Bank manufacturing process based on single-cell cloning. By integrating the VIPS™ platform for image-verified single-cell cloning and seeding together with CellMetric for automated clonal outgrowth imaging, the workflow supports traceable, high-confidence clone selection, an essential foundation for GMP-ready Master Cell Banks and downstream clinical manufacturing.
This approach enables the identification and expansion of genetically intact clones, strengthening the overall safety profile, ensuring consistent batch manufacturing and supporting the clinical robustness of iPSC-based therapies.
The featured panelists will discuss a workflow-centric approach to optimizing single-cell cloning for iPSC programs, spanning early clone establishment, culture condition selection and the transition toward GMP-ready Master and Working Cell Banks. Drawing on real-world development experience, the session will explore how media and matrix choices influence clonal performance, how cellular stress contributes to clonal drift and genetic instability and how upstream workflow design can mitigate these risks without relying on project-specific datasets.
The discussion will also highlight where single-cell recloning (“clonal reset”) and staged genetic integrity monitoring can be integrated into broader upstream strategies to support consistent, scalable and regulatory ready iPSC manufacturing. Attendees will gain practical insight into building robust single-cell cloning workflows, supported by image-verified technologies, that balance scientific rigor with real-world development constraints.
Register for this webinar to learn how iPSC manufacturing workflows can support genetically stable clones, GMP-ready cell banks and consistent clinical manufacturing.
Speakers
Noud Drummen, Field Application Scientist, Nova Biomedical
Noud Drummen partners with Cell Line Development teams across Europe, the Middle East and Africa to optimize workflows, streamline processes and drive innovation in laboratory operations, with a strong focus on the Solentim solutions. Noud combines a strong scientific foundation with deep knowledge of the Life Sciences market to help laboratories enhance efficiency and accuracy in single-cell seeding, culture monitoring and confident clone selection.
Silvia Rosati, Research Scientist, Process Development Lab, Evotec (Modena)
Silvia Rosati is a Research Scientist in the Gene & Stem Cell Therapy group at Evotec in Modena, Italy. Within the Process Development Laboratory, she supports the advancement of ATMP programs through the development, optimization and standardization of iPSC-based workflows. Her work spans iPSC culture and differentiation, seed bank generation, gene editing and pre-GMP process development, enabling the transition toward GMP manufacturing.
Silvia also contributes to the design and implementation of GMP compliant procedures, ensuring that processes are robust, scalable and aligned with regulatory expectations. Through her work, she supports Evotec’s mission to deliver high-quality, next generation cell and gene therapy solutions.
Evotec SE is a global biotechnology company active in drug discovery and early-stage development. It collaborates with pharmaceutical companies, biotech firms and foundations to accelerate the development of innovative therapies. The company brings together deep knowledge of disease biology expertise, advanced technology platforms and highly industrialized R&D processes. Its portfolio includes a dedicated cell therapy business unit that plays a central role in advancing next generation therapeutic solutions, with a particular focus on developing iPSC-based therapies.
Who Should Attend?
This webinar will appeal to:
- Cell Therapy Scientists and Developers working on iPSC derived clinical products
- Upstream Process Development and MSAT Scientists (CGT and iPSC)
- CDMO Platform teams supporting iPSC-based therapeutics
- Translational Research and Cell Banking teams preparing for GMP transfer
- Scientists responsible for single cell cloning, clone selection and early manufacturing decisions
- Anyone involved in designing robust, scalable and compliant iPSC workflows for therapeutic applications
What You Will Learn
Attendees will gain insight into:
- Why single-cell cloning variability is a major upstream risk factor in iPSC programs
- How media, matrix and handling conditions influence early clonal outgrowth and stability
- Where cellular stress contributes to clonal drift and genetic integrity risk
- When single-cell recloning can be used strategically to mitigate the effects of genomic instability
- Why genetically stable starting materials are essential for clinical grade iPSC manufacturing
- How to design upstream workflows that support GMP-ready iPSC banking that ensure high-quality starting materials
Xtalks Partner
Nova Biomedical
Advanced Instruments and Nova Biomedical now operate under the same brand, combining decades of expertise in analytical instrumentation, R&D, and global customer support. Nova Biomedical provides scientific and analytical solutions for bioprocessing, spanning cell culture monitoring, cell line development, liquid handling quality assurance, osmolality testing, and process optimization to help biopharmaceutical organizations increase efficiency and advance scientific discovery with confidence.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account